Patented Science – Dramatically slows human aging
A Biotechnical Company, Protokinetix has researched and produced Anti Aging Glycoproteins (AAGP™)
Dr. John Todd
President & CEO
President and Chief Executive
Officer of ProtoKinetix Inc. Dr. Todd is a Fellow of the Royal College of
Surgeons of Canada
and has been a practicing general surgeon for over 25 years. Prior to medicine,
he served for 5 years as a technical officer in the Canadian Military. He also
designed and built a Cable television system for Canadian Forces Base Shilo, Manitoba. In addition to
his surgical practice, which includes a high percentage of cancer patients, Dr.
Todd participated in and directed the clinical aspects of a breast cancer
research project studying the efficacy of Mammastatin.
Dr. Maximilien Arella
Chairman of the ProtoKinetix
Scientific Advisory Board. Dr. Arella is a Professor at the Microbiology and
Biotechnology Research Centre, Institut Armand-Frappier, University du Quebec,
where he has worked for the past 22 years. He has extensive international
experience in the field of molecular biology and monoclonal antibody
development, as well as 5 years experience as Chairman of the Virology
Institute at Armand-Frappier.
Dr. Jean-Charles Quirion
Member of Advisory Board
Member of the ProtoKinetix
Scientific Advisory Board. Professeur Quirion brings to ProtoKinetix 20 years of
research experience in synthetic organic chemistry and ten years of management
of industrial projects. His extensive contributions in the synthesis of new
chemical entities for New Drug Discovery in the areas of cancer will be of
enormous benefit to ProtoKinetix development of therapeutics for the treatment
of malignancies. Jean-Charles' research work has resulted in the development of
several new substances for anti-HIV, anti-inflammatory and anti-cancer drugs.
Mr. C. Fred Whittaker
Board of Directors
Member of the ProtoKinetix Board
of Trustees. Mr. Whittaker has been a Chartered Accountant for 39 years and is
the senior partner in the firm of Whittaker and Associates. He has many years
experience of working with private and public companies.
Dr. Geraldine Castelot-Deliencourt
Dr. Castelot-Deliencourt has many years experience in synthetic organic chemistry and in the synthesis of new chemical entities. She has been instrumental in the development of the synthetic antifreeze glycoproteins and at this time is directing the research to develop new compounds and is coordinating the production of the synthetic AAGP™ for research purposes. Dr. Castelot-Deliencourt is credited with the development of the platform technology which has led to the development of the family of synthetic AFGP.